Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 10/20 | 0.45 |
| ▸ | F2 | P00734 | 7/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825224 | 0.78 | F10 (0.49) | CYP2C9CYP2C19MMP2F10F2 | |
| SCHEMBL13456457 | 0.78 | GAA (0.45) | CYP2C9CYP2C19MMP2ADAMTS5GAA | |
| SCHEMBL8289817 | 0.78 | F10 (0.52) | MMP2F10F2PRSS1PRSS2 | |
| SCHEMBL8353843 | 0.77 | F2 (0.43) | F10F2PRSS1 | |
| SCHEMBL8358012 | 0.77 | F2 (0.52) | F10F2PRSS1 | |
| SCHEMBL16919021 | 0.75 | TLR2 (0.39) | — | |
| SCHEMBL17366090 | 0.74 | SLC1A3 (0.50) | MMP2MAPTKMT2AMEN1 | |
| SCHEMBL8358318 | 0.72 | F2 (0.51) | F10F2 | |
| SCHEMBL14472554 | 0.72 | MAPT (0.44) | CYP2C9CYP2C19F10F2GAA | |
| SCHEMBL13456454 | 0.72 | F10 (0.54) | F10F2KMT2APRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068272-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068272-A1 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS | PLAU, PLAUR, HPN | CYP2C9 1257/4885CYP2C19 1728/4885MMP2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.